Clinical trial
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small…
NCT00005972 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00005972 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer |
| Official title | Phase II Trial of Gemcitabine/Irinotecan as Second Line Therapy for Small Cell Lung Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, irinotecan hydrochloride |
| Enrollment | 73 |
| Start date | May 1, 2000 |
| Primary completion | Oct 1, 2006 |
| Completion | Feb 1, 2008 |
| First posted | Mar 24, 2004 |
| Last update posted | Jul 14, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: